Optimizing Cardiorenal-Metabolic Health: A Managed Care Guide to Integrating SGLT2 Inhibitor Therapy

Program Description

Cardiorenal-metabolic (CRM) syndrome is the overlap of type 2 diabetes, heart failure (HF), and chronic kidney disease (CKD), and the condition presents clinical and economic burdens due to progressive organ damage and frequent hospitalizations. While SGLT2 inhibitors have revolutionized therapy for patients with and without diabetes, their optimal use is often limited by clinical inertia. Additionally, across the CRM continuum, SGLT2 inhibitors consistently reduce hospitalizations and adverse events that drive high health care costs. The rapid expansion of clinical indications for SGLT2 inhibitors beyond glycemic control has created a shift in the management of CRM conditions. Their appropriate use, however, requires that pharmacists and managed care professionals be adequately informed about guideline-directed evidence to optimize clinical and economic outcomes. This program balances clinical evidence for SGLT2 inhibitors with payer application. The expert-led discussion will provide the tools to design value-based formularies and integrated care models to improve utilization of SGLT2 inhibitors while managing the total cost of care.

Target audience: Managed care pharmacists
Type of activity: Application
Release date: April 30, 2026
Expiration date: April 30, 2027
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify the interconnected pathophysiology, clinical progression, and economic burden of cardiorenal-metabolic diseases to improve early risk stratification and opportunities for integrated management.
• Analyze current clinical evidence, guideline recommendations, and comparative data for SGLT2 inhibitors across the cardiorenal-metabolic spectrum to inform care strategies for patients.
• Illustrate evidence-based formulary and benefit design strategies that incorporate real-world evidence, cost-effectiveness analyses, and outcomes-based contracting models to improve patient access, individualized care, optimize adherence, and align the total cost of care with the clinical value of SGLT2 inhibitors.

Accreditation

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-26-103-H01-P. The activity is available for CE credit through April 30, 2027.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Sneha Baxi Srivastava, PharmD, BCACP, CDCES, DipACLM, FADCES, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Xeris Pharmaceuticals

Amanda Williams, PharmD, RPh, has the following relevant financial relationships with ineligible companies to disclose:

Employee of PBM: Gainwell Technologies

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Liza Patel, PharmD, RPh; Rose Buszka, PharmD, BCPS, CHCP; Adam C Welch, PharmD, MBA, FAPhA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms